2,5-dimethyl-3H-thieno[2,3-d]pyrimidin-4-one | 782462-55-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: 2,5-dimethyl-3H-thieno[2,3-d]pyrimidin-4-one
• CAS: 782462-55-9
• 化学式: C₈H₈N₂OS
• mdl: MFCD22207442
• 分子量: 180.23
• InChiKey: ISGNXGAQSDXHOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  69.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,5-dimethyl-3H-thieno[2,3-d]pyrimidin-4-one 在 三氯氧磷 作用下， 生成 4-chloro-2,5-dimethylthieno[2,3-d]pyrimidine
  参考文献：
  名称：

  Microwave-assisted synthesis of potent PDE7 inhibitors containing a thienopyrimidin-4-amine scaffold

  摘要：

  噻唑嘧啶-4-胺已被合成、评估并建模为磷酸二酯酶抑制剂。

  DOI：

  10.1039/c4ob00175c
• 作为产物：
  描述：

  、 硫代乙酰胺 以 neat (no solvent) 为溶剂， 以48%的产率得到2,5-dimethyl-3H-thieno[2,3-d]pyrimidin-4-one
  参考文献：
  名称：

  Microwave-assisted synthesis of potent PDE7 inhibitors containing a thienopyrimidin-4-amine scaffold

  摘要：

  噻唑嘧啶-4-胺已被合成、评估并建模为磷酸二酯酶抑制剂。

  DOI：

  10.1039/c4ob00175c

文献信息

• SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20150329556A1

  公开（公告）日：2015-11-19

  The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR 1 (R 1 is a hydrogen atom or an optionally substituted hydrocarbon group), is a single bond or a double bond, R 2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X′ is S, O, SO, or CH 2 ), and at least one of ring B and ring C has substituent(s), provided that N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]2 hydroxypropyl}5,6 dimethyl 4 oxo 1,4 dihydrothieno[2,3-d]pyrimidine-2-carboxamide is excluded, or a salt thereof.

  本发明提供了一种新型酰胺衍生物，具有基质金属蛋白酶抑制活性，并且作为药用剂是有用的，该化合物由以下式(I)表示，其中环A是一个可选择取代的含氮杂环，环B是一个可选择取代的单环同核环或可选择取代的单环杂环，Z是N或NR1（R1是氢原子或可选择取代的碳氢基团），是一个单键或双键，R2是氢原子或可选择取代的碳氢基团，X是一个具有1到6个原子的可选择取代的间隔物，环C是（1）一个可选择取代的同核环或（2）一个除了由（II）表示的环之外的可选择取代的杂环（X′是S、O、SO或CH2），并且环B和环C中至少有一个有取代基，但不包括N-(1S,2R)-1-(3,5-二氟苄基)-3-[(3-乙基苄基)氨基]2-羟基丙基}5,6-二甲基-4-氧代-1,4-二氢噻唑并[2,3-d]嘧啶-2-羧酰胺，或其盐。
• 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors
  申请人：Ji Qun-Sheng

  公开号：US20070032512A1

  公开（公告）日：2007-02-08

  Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X 1 , X 2 , X 3 , and Q 1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

  该式化合物及其药用可接受盐，其中X1、X2、X3和Q1的定义如本文所述，可抑制IGF-1R酶，并用于治疗和/或预防增生性疾病，如癌症、炎症、牛皮癣、过敏/哮喘、免疫系统疾病和病症以及中枢神经系统疾病和病症。
• New piperidinylamino-thieno[2,3-d] pyrimidine compounds
  申请人：——

  公开号：US20040248904A1

  公开（公告）日：2004-12-09

  The invention relates to 5-HT receptor antagonists. Novel piperidinylamino-thieno[2,3-d]pyrimidine compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as anxiety, depression, schizophrenia, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

  本发明涉及5-HT受体拮抗剂。公开了由式I表示的新型哌啶基氨基噻吩[2,3-d]嘧啶化合物的合成和用途，用于治疗直接或间接由5-HT受体介导的疾病。这些疾病包括中枢神经系统疾病，如焦虑、抑郁、精神分裂症、神经损伤、中风和偏头痛。还包括其制备方法、新型中间体和药物盐。
• N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
  申请人：Cai Xiong Sui

  公开号：US20070213305A1

  公开（公告）日：2007-09-13

  Disclosed are N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs thereof, represented by the Formulae I-II: wherein Ar, R 1 -R 4 and R 10 are defined herein. The present invention relates to the discovery that compounds having Formulae I-II are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及公开的N-烷基-N-芳基噻唑嘧啶-4-胺及其类似物，其由式I-II表示：其中Ar、R1-R4和R10如本文所定义。本发明关于发现具有式I-II的化合物是caspase的激活剂和凋亡诱导剂。因此，本发明的caspase激活剂和凋亡诱导剂可用于在多种临床情况下诱导细胞死亡，其中发生异常细胞的不受控制的生长和扩散。
• NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS
  申请人：Trovis Pharmaceuticals LLC

  公开号：EP1622914B1

  公开（公告）日：2011-06-01